Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 5/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GUSB | P08236 | 1/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239638 | 0.85 | RAB9A (0.62) | SMPD1RAB9AMAOBADAM17ALDH1A1 | |
| SCHEMBL366501 | 0.85 | RAB9A (0.62) | SMPD1RAB9AMAOBADAM17ALDH1A1 | |
| SCHEMBL19962767 | 0.82 | RAB9A (0.70) | SMPD1RAB9AMAOBALDH1A1MAPT | |
| SCHEMBL12687869 | 0.82 | CA1 (0.57) | SMPD1RAB9AMAOB | |
| SCHEMBL20463317 | 0.82 | ALDH1A1 (0.74) | SMPD1RAB9AMAOBALDH1A1MAPT | |
| SCHEMBL29741480 | 0.80 | MAOB (0.81) | SMPD1RAB9AMAOB | |
| SCHEMBL18664184 | 0.80 | MAOB (0.81) | SMPD1RAB9AMAOB | |
| SCHEMBL25998778 | 0.79 | SMPD1 (0.59) | SMPD1RAB9AADAM17SPHK2SPHK1 | |
| SCHEMBL22386738 | 0.78 | RAB9A (0.68) | SMPD1RAB9AMAOBADAM17ALDH1A1 | |
| SCHEMBL22386762 | 0.77 | RAB9A (0.67) | SMPD1RAB9AMAOBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | SMPD1 713/4885RAB9A 2424/4885MAOB 185/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | SMPD1 25/4885RAB9A 573/4885MAOB 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.